Table 4.
Measures of disease activity (baseline to LTFU) in the highest and lowest quartiles of patients, by cumulative dose or time, and continuous or noncontinuous sc IFN beta-1a treatment.
| Cumulative dose of sc IFN beta-1a |
Cumulative time on sc IFN beta-1a |
Noncontinuous versus continuous IFN beta-1a, 44 µg sc tiw |
||||
|---|---|---|---|---|---|---|
| MIN | MAX | MIN | MAX | Noncontinuous | Continuous | |
| (n = 96) | (n = 95) | (n = 96) | (n = 95) | (n = 91) | (n = 45) | |
| Mean ( ± SD) annualized relapse rate | 0.72 ± 0.55 | 0.52 ± 0.51 | 0.76 ± 0.55 | 0.51 ± 0.49) | 0.61 ± 0.56 | 0.51 ± 0.54 |
| Median (range) | 0.67 (0.00–2.34) | 0.396 (0.00–2.53) | 0.68 (0.00–2.57) | 0.394 (0.00–2.53 | 0.52 (0.00–2.34) | 0.27 (0.00–2.53) |
| Relapse-free, n (%) of patients | 7 (7.3) | 15 (15.8) | 7 (7.3) | 16 (16.8) | 15 (16.5) | 6 (13.3) |
| 3-month confirmed EDSS progression, n (%) of patients | 62 (64.6) | 51 (53.7) | 65 (67.7) | 51 (53.7) | 59 (64.8) | 21 (46.7) |
| Converted to SPMS, n (%) of patients | 21 (21.9) | 13 (13.7) | 28 (29.2) | 15 (15.8) | 23 (25.3) | 5 (11.1) |
| Mean ( ± SD) change in T2 burden of disease, % | 68.0 ± 159.0a | 28.2 ± 77.4b | 86.2 ± 183.1c | 44.3 ± 119.5d | 41.3 ± 145.9 | 32.8 ± 72.2 |
| Median (range) | 21.3 (−51.9–1054.8) | 3.7 (−64.7–413.9) | 23.5 (−51.9–1054.8) | 1.5 (−64.7–651.1) | 3.2 (−64.7–1054.8) | 6.2 (−54.3–304.2) |
Data are for patients completing the LTFU.
an = 82; bn = 92; cn = 78; dn = 91.
EDSS, Expanded Disability Status Scale; IFN, interferon; LTFU, long-term follow up; MAX, maximum (highest quartile); MIN, minimum (lowest quartile); sc, subcutaneous; SD, standard deviation; SPMS, secondary progressive multiple sclerosis; tiw, three times weekly.